Clinical trial
A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial To Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy in Essential Hypertension Subjects Inadequately Controlled by D064 Monotherapy
NCT05526703 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial To Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy in Essential Hypertension Subjects Inadequately Controlled by D064 Monotherapy
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 28, 2022
- Completion date
- October 31, 2023
- Enrollment
- 108 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.